Belldegrun AS - Search Results

1

Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma.

Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. Kim HL, et al. Among authors: belldegrun as. J Urol. 2004 May;171(5):1810-3. doi: 10.1097/01.ju.0000121440.82581.d3. J Urol. 2004. PMID: 15076282

2

Collecting duct renal cell carcinoma: clinical study of a rare tumor.

Chao D, Zisman A, Pantuck AJ, Gitlitz BJ, Freedland SJ, Said JW, Figlin RA, Belldegrun AS. Chao D, et al. Among authors: belldegrun as. J Urol. 2002 Jan;167(1):71-4. doi: 10.1016/s0022-5347(05)65385-2. J Urol. 2002. PMID: 11743278

3

Tumor markers for the early detection of bladder cancer.

Han KR, Pantuck AJ, Belldegrun AS, Rao JY. Han KR, et al. Among authors: belldegrun as. Front Biosci. 2002 Jan 1;7:e19-26. doi: 10.2741/A901. Front Biosci. 2002. PMID: 11779696 Review.

4

Cryosurgical ablation of renal tumors using 1.5-millimeter, ultrathin cryoprobes.

Pantuck AJ, Zisman A, Cohen J, Belldegrun A. Pantuck AJ, et al. Urology. 2002 Jan;59(1):130-3. doi: 10.1016/s0090-4295(01)01502-3. Urology. 2002. PMID: 11796298

5

Mathematical model to predict individual survival for patients with renal cell carcinoma.

Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, deKernion JB, Figlin RA, Belldegrun AS. Zisman A, et al. Among authors: belldegrun as. J Clin Oncol. 2002 Mar 1;20(5):1368-74. doi: 10.1200/JCO.2002.20.5.1368. J Clin Oncol. 2002. PMID: 11870181

6

Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants.

Pantuck AJ, Matherly J, Zisman A, Nguyen D, Berger F, Gambhir SS, Black ME, Belldegrun A, Wu L. Pantuck AJ, et al. Hum Gene Ther. 2002 May 1;13(7):777-89. doi: 10.1089/10430340252898966. Hum Gene Ther. 2002. PMID: 11975845

7

Changing concepts in the management of renal oncocytoma.

Chao DH, Zisman A, Pantuck AJ, Freedland SJ, Said JW, Belldegrun AS. Chao DH, et al. Among authors: belldegrun as. Urology. 2002 May;59(5):635-42. doi: 10.1016/s0090-4295(01)01630-2. Urology. 2002. PMID: 11992832 Review. No abstract available.

8

A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon.

Han KR, Pantuck AJ, Belldegrun AS. Han KR, et al. Among authors: belldegrun as. Curr Urol Rep. 2002 Feb;3(1):11-2. doi: 10.1007/s11934-002-0004-9. Curr Urol Rep. 2002. PMID: 12084213 No abstract available.

9

Minimally invasive ablative approaches in the treatment of renal cell carcinoma.

Janzen N, Zisman A, Pantuck AJ, Perry K, Schulam P, Belldegrun AS. Janzen N, et al. Among authors: belldegrun as. Curr Urol Rep. 2002 Feb;3(1):13-20. doi: 10.1007/s11934-002-0005-8. Curr Urol Rep. 2002. PMID: 12084214 Review.

10

Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype.

Zisman A, Chao DH, Pantuck AJ, Kim HJ, Wieder JA, Figlin RA, Said JW, Belldegrun AS. Zisman A, et al. Among authors: belldegrun as. J Urol. 2002 Sep;168(3):950-5. doi: 10.1016/S0022-5347(05)64549-1. J Urol. 2002. PMID: 12187197

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters